与慢性胰腺炎和胰腺癌相关的肠道微生物组变化:系统评价和荟萃分析。
Gut microbiome changes associated with chronic pancreatitis and pancreatic cancer: a systematic review and meta-analysis.
机构信息
Department of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
出版信息
Int J Surg. 2024 Sep 1;110(9):5781-5794. doi: 10.1097/JS9.0000000000001724.
BACKGROUND
The study of changes in the microbiome in chronic pancreatitis (CP) and pancreatic ductal adenocarcinoma (PDAC) holds significant potential for developing noninvasive diagnostic tools as well as innovative interventions to alter the progression of diseases. This systematic review and meta-analysis aimed to analyze in detail the taxonomic and functional characteristics of the gut microbiome in patients with CP and PDAC.
METHODS
Two researchers conducted a systematic search across public databases to gather all published research up to June 2023. Diversity and gut microbiota composition are the main outcomes the authors focus on.
RESULTS
This meta-analysis included 14 studies, involving a total of 1511 individuals in the PDAC ( n =285), CP ( n =342), and control ( n =649) groups. Our results show a significant difference in the composition of gut microbiota between PDAC/CP patients compared to healthy controls (HC), as evidenced by a slight decrease in α-diversity, including Shannon (SMD=-0.33; P =0.002 and SMD=-0.59; P <0.001, respectively) and a statistically significant β-diversity ( P <0.05). The pooled results showed that at the phylum level, the proportion of Firmicutes was lower in PDAC and CP patients than in HC patients. At the genus level, more than two studies demonstrated that four genera were significantly increased in PDAC patients compared to HC (e.g. Escherichia-Shigella and Veillonella ). CP patients had an increase in four genera (e.g. Escherichia-Shigella and Klebsiella ) and a decrease in eight genera (e.g. Coprococcus and Bifidobacterium ) compared to HC. Functional/metabolomics results from various studies also showed differences between PDAC/CP patients and HC. In addition, this study found no significant differences in gut microbiota between PDAC and CP patients.
CONCLUSIONS
Current evidence suggests changes in gut microbiota is associated with PDAC/CP, commonly reflected by a reduction in beneficial species and an increase in the pathogenic species. Further studies are needed to confirm these findings and explore therapeutic possibilities.
背景
研究慢性胰腺炎(CP)和胰腺导管腺癌(PDAC)中微生物组的变化,为开发非侵入性诊断工具以及改变疾病进展的创新干预措施提供了重要潜力。本系统综述和荟萃分析旨在详细分析 CP 和 PDAC 患者肠道微生物组的分类和功能特征。
方法
两名研究人员对公共数据库进行了系统搜索,以收集截至 2023 年 6 月发表的所有研究。多样性和肠道微生物群落组成是作者关注的主要结果。
结果
这项荟萃分析包括 14 项研究,共纳入 1511 名 PDAC(n=285)、CP(n=342)和对照组(n=649)患者。我们的结果表明,PDAC/CP 患者与健康对照组(HC)相比,肠道微生物群落组成存在显著差异,表现在 α-多样性略有下降,包括 Shannon(SMD=-0.33;P=0.002 和 SMD=-0.59;P<0.001)和统计学显著的 β-多样性(P<0.05)。汇总结果显示,在门水平上,PDAC 和 CP 患者的厚壁菌门比例低于 HC 患者。在属水平上,超过两项研究表明,与 HC 相比,PDAC 患者中有四种属显著增加(例如大肠杆菌-志贺氏菌和韦荣氏球菌)。CP 患者与 HC 相比,有四种属增加(例如大肠杆菌-志贺氏菌和克雷伯氏菌)和八种属减少(例如毛螺菌科和双歧杆菌)。来自不同研究的功能/代谢组学结果也显示 PDAC/CP 患者与 HC 之间存在差异。此外,本研究未发现 PDAC 和 CP 患者之间肠道微生物群存在显著差异。
结论
目前的证据表明,肠道微生物群的变化与 PDAC/CP 相关,通常表现为有益物种减少和致病物种增加。需要进一步的研究来证实这些发现并探索治疗的可能性。